Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Quebec program combats RSV in northern babies

Véronique Morin
CMAJ January 23, 2017 189 (3) E122; DOI: https://doi.org/10.1503/cmaj.109-5368
Véronique Morin
Montréal, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

All Inuit babies born in Nunavik, northern Quebec, will receive injections of palivizumab (Synagis) to protect against respiratory syncytial virus (RSV), a lower respiratory virus they are particularly prone to contracting, under a new Quebec Ministry of Health directive.

The therapy is currently only given to premature babies and those born with life-threatening cardiac or pulmonary conditions.

Up to half the babies born in Nunavik who are admitted to hospital have respiratory tract infections, says Dr. Anna Banerji, a clinical pediatrician and researcher at the University of Toronto. Her latest research, published in CMAJ Open, estimates that 120 babies out of 250 born in 2009, or 48%, were admitted to hospital, mostly in the Nunavik region, due to RSV.

“Worldwide, it is the number one cause of babies being admitted to hospitals. So there is nothing new about this virus. But what is new is the number — the actual rate of admission in this case — which is the highest ever documented in the world.” According to the US Centers for Disease Control and Prevention, most babies contract RSV by two years of age, but fewer than 2% are admitted to the hospital.

Banerji says Quebec’s directive is a positive step toward curbing the high rate of hospital admissions due to RSV in the north.

But the new directive, which came into effect Dec. 1, was a complete surprise for the director of public health in Nunavik. “I was not consulted on this,” said Dr. Françoise Bouchard, who has requested a meeting with officials at Quebec’s Ministry of Health about the directive. “We have several concerns. For one, this immunoglobulin therapy has never been tested on healthy babies.”

Although clinical studies show there are benefits to giving palivizumab to premature babies and those deemed at high risk, she argues that the risk–benefit ratio might not be the same for healthy newborns. Bouchard is also concerned about the increased workload the new directive will put on a nursing staff who are already working to capacity.

Figure1

One study estimates that 48% of babies born in Nunavik in 2009 were admitted to hospital with respiratory syncytial virus.

Image courtesy of RyersonClark/iStock

The new directive requires that every newborn receive injections of palivizumab every month for four or five months. This means nurses will have to deliver hundreds of new shots.

In addition to taxing staff, it will require young parents to make the journey to the hospital every month for their baby’s injections, says Nunavik nurse Amélie Drôlet. “It will be difficult to ensure continuity,” she says.

Officials also question whether the benefits outweigh the financial costs. Each course of treatment will cost Quebec taxpayers a minimum of $8000.

But for Dr. Johanne Morel, a pediatrician at the Montréal Children’s Health Hospital, and a consultant in the north, the preventive value of palivizumab makes it well worth the expense — particularly given the high costs of treating the two or three babies each year who are so sick they need to be treated at the Montreal hospital’s intensive care unit (ICU).

“It is very expensive to transport a child from the north to Montréal, and admitting a baby to ICU costs tens of thousands of dollars,” Morel says. She says immunizing the babies is worth the effort and expense.

Quebec is the first province to immunize healthy infants against the virus. Other regions, such as Nunavut and the Northwest Territories, which also have a high incidence, are discussing the issue but have not yet taken similar steps.

“They probably want to wait and see how this goes in Nunavik,” says Morel. “They’ve asked us to keep a registry for evaluation.”

Immunizations will run until May 1, 2017. It is recommended the measure be re-evaluated annually.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (3)
CMAJ
Vol. 189, Issue 3
23 Jan 2017
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Quebec program combats RSV in northern babies
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Quebec program combats RSV in northern babies
Véronique Morin
CMAJ Jan 2017, 189 (3) E122; DOI: 10.1503/cmaj.109-5368

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Quebec program combats RSV in northern babies
Véronique Morin
CMAJ Jan 2017, 189 (3) E122; DOI: 10.1503/cmaj.109-5368
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Trudeau promises to boost federal health transfers when the pandemic is over
  • Does shaming have a place in public health?
  • Should Canada aim for #CovidZero?
Show more News

Similar Articles

Collections

  • Topics
    • Public health
    • Aboriginal health

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire